Showing 5561-5570 of 9401 results for "".
- Study: Recell System Plus Dermabrasion Speeds Acne Scar Healinghttps://practicaldermatology.com/news/study-recell-system-plus-dermabrasion-speeds-acne-scar-healing/2460154/When combined with dermabrasion, the RECELL Autologous Cell Harvesting Device speeds the healing of facial acne scars, according to a study in Aesthetic Plastic Surgery. The RECELL System uses a small
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a derm
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the
- With Fibrocell Acquisition, Castle Creek Expands Late-Stage EB Pipelinehttps://practicaldermatology.com/news/with-fibrocell-acquisition-castle-creek-expands-late-stage-eb-pipeline/2460149/Castle Creek Pharmaceutical Holdings, Inc. acquired Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings’ subsidiary,
- Increased Adherence, Symptom Improvement Seen When Psoriasis Patients Switch to IL-17 Blockershttps://practicaldermatology.com/news/increased-adherence-symptom-improvement-seen-when-psoriasis-patients-switch-to-il-17-blockers/2460147/New data points to increased adherence and improvement in symptoms for psoriasis patients who switch to interleukin-17 inhibitors. The study, which was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime, was presented at the National Association of Specialty Pharma
- SENTÉ Partners with Scientis to Introduce Cysperahttps://practicaldermatology.com/news/sente-partners-with-scientis-to-introduce-cyspera/2460146/SENTÉ is partnering with Scientis, a Swiss dermatology company dedicated to developing novel dermo-cosmetic solutions to address skin pigmentation concerns, to introduce Cyspera®. Cyspera, a physician exclusive skincare product, is a novel intensive
- Melanoma Breakthrough: Researchers Discover Why Some Patients Respond to Immunotherapyhttps://practicaldermatology.com/news/melanoma-breakthrough-researchers-discover-why-some-patients-respond-to-immunotherapy-yet-others-dont/2460143/Israeli researchers now know why 60 percent of patients with metastatic melanoma do not respond to immunotherapy. After examining tumors of 116 patients using proteomics, the researchers found the non-responding patients tended to have lower fatty acid metabolism, meaning that their enz
- Innovations In Skin Of Color Dermatology Award Presented to Dr. Andrew F. Alexishttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-presented-to-dr-andrew-f-alexis/2460140/The Journal of Drugs in Dermatology (JDD) presented dermatologist Andrew F. Alexis, MD, MPH, with the Innovations in Skin of Color Dermatology Award at Skin of Color Update, formerly Skin of Color Seminar Series, held September 7 and 8 in New York. The award recognizes individuals who ha
- Lilly’s Oral JAK Inhibitor Plus Steroids Improves AD Symptomshttps://practicaldermatology.com/news/lillys-oral-jak-inhibitor-plus-steroids-improves-ad-symptoms/2460134/Adding the oral JAK inhibitor baricitinib to standard-of-care topical corticosteroids significantly improved atopic dermatitis disease severity, measured by the validated Investigator's Global Assessment for AD (vIGA) score of "clear or almost clear" skin (vIGA 0, 1), the primary en
- ASDS 2018 Survey: Skin Cancer Treatments and Cosmetic Procedures are on the Risehttps://practicaldermatology.com/news/asds-2018-survey-skin-cancer-treatments-and-cosmetic-procedures-are-on-the-rise/2460133/American Society for Dermatologic Surgery (ASDS) member dermatologists performed more than 12.5 million medical and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a 60 percent increase since 2012, according to the 2018 ASDS